BioProcess Algae LLC, a sustainable algal feedstocks company, and KD-Pharma Bexbach GmbH, part of the Fat & Lipids Division of Bioseutica BV, a leading producer of highly purified pharmaceutical-grade Omega-3 fatty acids, announced today that they have entered a commercial supply agreement for the production of EPA-rich omega-3 oils for use in concentrated EPA products for nutritional and/or pharmaceutical applications. Under the agreement, BioProcess Algae will supply microalgal oils, which will be refined by KD-Pharma's proprietary Supercritical Fluid Technology (KD-pur(R)) to produce highly-concentrated vegetable sourced EPA oils.
"We are very pleased to be able to work side-by-side with the industry leader for high-quality, highly-purified omega-3 oils," said Tim Burns, CEO of BioProcess Algae. "Our strategy is to continue to expand our colocation operations by growing high-quality feedstock at attractive prices. We intend to integrate additional off-takes to increase our operational efficiency, continue to gain economies of scale and to enhance profitability, and this agreement will enable us to expand commercial development toward this goal. We see many synergies with KD-Pharma and are excited to be working together."
"Bioseutica is committed to identifying the highest quality and most sustainable sources for our natural ingredients," said Peter Lembke, Vice President & Business Development Manager, Bioseutica. "From the beginning of our relationship, it was clear that BioProcess Algae shared our commitment to the environment without compromising product quality. Securing access to their algae oil will enable us to offer a unique, sustainable vegetable-based EPA-rich product that cannot be found in the marketplace today."